Fluicell AB Net Assets

Latest as of March 2026: Skr14.21 Million SEK ≈ $1.53 Million USD

Fluicell AB net assets. Based on the latest financial reports, Fluicell AB (FLUI) has net assets worth Skr14.21 Million SEK (≈ $1.53 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr20.77 Million ≈ $2.23 Million USD) and total liabilities (Skr6.56 Million ≈ $705.64K USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore FLUI shareholders equity momentum to track the company's year-over-year net asset growth rate.

Key Net Assets Metrics

Metric	Value
Current Net Assets	Skr14.21 Million
% of Total Assets	68.43%
Annual Growth Rate	22.33%
5-Year Change	-42.96%
10-Year Change	492.12%
Growth Volatility	1262.7

Net Assets of Fluicell AB (2014–2025)

Net assets of Fluicell AB from 2014 to 2025. This chart illustrates how Fluicell AB's net assets have evolved over time, based on quarterly financial data. See net asset quality index of Fluicell AB to measure how much of total assets are equity-financed.

Annual Net Assets for Fluicell AB (2014–2025)

The table below shows the annual net assets of Fluicell AB from 2014 to 2025. For live market cap and overall valuation, see market value of Fluicell AB.

Year	Net Assets	Change
2025-12-31	Skr10.90 Million ≈ $1.17 Million	-43.32%
2024-12-31	Skr19.23 Million ≈ $2.07 Million	+4425.65%
2023-12-31	Skr425.00K ≈ $45.74K	-98.19%
2022-12-31	Skr23.45 Million ≈ $2.52 Million	+22.68%
2021-12-31	Skr19.11 Million ≈ $2.06 Million	-1.98%
2020-12-31	Skr19.50 Million ≈ $2.10 Million	+90.69%
2019-12-31	Skr10.22 Million ≈ $1.10 Million	-56.25%
2018-12-31	Skr23.37 Million ≈ $2.52 Million	+143.93%
2017-12-31	Skr9.58 Million ≈ $1.03 Million	+420.48%
2016-12-31	Skr1.84 Million ≈ $198.12K	+165.27%
2015-12-31	Skr694.00K ≈ $74.69K	-41.54%
2014-12-31	Skr1.19 Million ≈ $127.76K	--

Equity Component Analysis

This analysis shows how different components contribute to Fluicell AB's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have decreased by 13462905000.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Fluicell AB Net Assets Breakdown (December 2025)

Fluicell AB net assets breakdown by equity component as of December 2025.

Component	Amount	Percentage
Common Stock	Skr2.75 Million	25.20%
Other Comprehensive Income	Skr10.34 Million	94.82%
Other Components	Skr134.71 Million	1235.76%
Total Equity	Skr10.90 Million	100.00%

Fluicell AB Competitors by Market Cap

The table below lists competitors of Fluicell AB ranked by their market capitalization.

Company	Market Cap
Adneo Ltd AU:AD1	$4.04 Million
REY Resources Ltd AU:REY	$4.04 Million
ModivCare Inc NASDAQ:MODV	$4.04 Million
Inspire Veterinary Partners, Inc. NASDAQ:IVP	$4.05 Million
Euro Menkul Kiymet Yatirim Ortakligi AS IS:EUYO	$4.03 Million
Pragma Inkaso S.A. WAR:PRI	$4.03 Million
Largo SAS PA:ALLGO	$4.03 Million
Revelation Biosciences Inc NASDAQ:REVB	$4.02 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Fluicell AB's equity between the two most recent reporting periods.

Equity Growth Insights

From 2024 to 2025, total equity changed from 19,234,000 to 10,901,000, a change of -8,333,000 (-43.3%).
Net loss of 8,332,000 reduced equity.
Other comprehensive income increased equity by 6,846,000.
Other factors decreased equity by 6,847,000.

Equity Change Factors (2024 to 2025)

Factor	Impact	Contribution
Net Income	Skr-8.33 Million	-76.43%
Other Comprehensive Income	Skr6.85 Million	+62.8%
Other Changes	Skr-6.85 Million	-62.81%
Total Change	Skr-	-43.32%

Book Value vs Market Value Analysis

This analysis compares Fluicell AB's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 203.55x
The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
The price-to-book ratio has increased from 3.02x to 203.55x over the analyzed period, suggesting growing market confidence.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2014-12-31	Skr9.05	Skr27.30	x
2015-12-31	Skr5.29	Skr27.30	x
2016-12-31	Skr14.03	Skr27.30	x
2017-12-31	Skr46.00	Skr27.30	x
2018-12-31	Skr84.20	Skr27.30	x
2019-12-31	Skr34.15	Skr27.30	x
2020-12-31	Skr0.35	Skr27.30	x
2021-12-31	Skr0.32	Skr27.30	x
2022-12-31	Skr0.35	Skr27.30	x
2023-12-31	Skr0.41	Skr27.30	x
2024-12-31	Skr16.25	Skr27.30	x
2025-12-31	Skr0.13	Skr27.30	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Fluicell AB utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): -76.43%
The company may be facing challenges in efficiently utilizing shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: -138.82%
• Asset Turnover: 0.32x
• Equity Multiplier: 1.69x
Recent ROE (-76.43%) is above the historical average (-664.95%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2014	-138.73%	-1174.10%	0.08x	1.41x	Skr-1.77 Million
2015	-545.16%	-267.23%	0.83x	2.46x	Skr-3.85 Million
2016	-268.88%	-187.86%	0.95x	1.51x	Skr-5.13 Million
2017	-77.96%	-710.08%	0.09x	1.20x	Skr-8.43 Million
2018	-62.89%	-1199.02%	0.05x	1.11x	Skr-17.04 Million
2019	-182.25%	-749.00%	0.12x	1.95x	Skr-19.66 Million
2020	-93.11%	-391.67%	0.19x	1.27x	Skr-20.10 Million
2021	-113.65%	-834.74%	0.10x	1.41x	Skr-23.63 Million
2022	-91.64%	-660.94%	0.10x	1.35x	Skr-23.83 Million
2023	-6248.00%	-795.51%	0.36x	21.98x	Skr-26.60 Million
2024	-80.64%	-834.37%	0.07x	1.33x	Skr-17.43 Million
2025	-76.43%	-138.82%	0.32x	1.69x	Skr-9.42 Million

Industry Comparison

This section compares Fluicell AB's net assets metrics with peer companies in the Biotechnology industry.

Industry Context

Industry: Biotechnology
Average net assets among peers: $177,426,563
Average return on equity (ROE) among peers: -118.59%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Fluicell AB (FLUI)	Skr14.21 Million	-138.73%	0.46x	$4.04 Million
2cureX AB (2CUREX)	$58.86 Million	-12.44%	0.07x	$1.13 Million
Ascelia Pharma AB (publ) (ACE)	$74.33 Million	-147.03%	0.17x	$7.35 Million
AcouSort AB (ACOU)	$78.63K	-354.63%	2.32x	$7.49 Million
Active Biotech AB (ACTI)	$55.60 Million	-67.09%	0.26x	$11.63 Million
Alzinova AB (ALZ)	$123.82 Million	-16.60%	0.08x	$7.32 Million
AlzeCure Pharma (ALZCUR)	$32.97 Million	-235.89%	0.38x	$76.18 Million
Annexin Pharmaceuticals AB (ANNX)	$13.71 Million	-366.46%	0.39x	$4.83 Million
Alligator Bioscience AB (ATORX)	$468.31 Million	-32.04%	0.09x	$1.10 Million
BioInvent International AB (BINV)	$885.82 Million	-48.47%	0.12x	$26.95 Million
BioArctic AB (publ) (BIOA-B)	$60.76 Million	94.77%	10.65x	$2.49 Billion

About Fluicell AB

ST:FLUI Sweden Biotechnology

Market Cap

$4.04 Million

Skr37.50 Million SEK

Market Cap Rank

#28939 Global

#643 in Sweden

Share Price

Skr27.30

Change (1 day)

+4.20%

52-Week Range

Skr7.95 - Skr57.20

All Time High

Skr188.78